563 related articles for article (PubMed ID: 17309576)
41. Effects of anaesthesia on fluid and solute transport in a C57BL6 mouse model of peritoneal dialysis.
Shin SK; Kamerath CD; Gilson JF; Leypoldt JK
Nephrol Dial Transplant; 2006 Oct; 21(10):2874-80. PubMed ID: 16877489
[TBL] [Abstract][Full Text] [Related]
42. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells.
Witowski J; Korybalska K; Ksiazek K; Wisniewska-Elnur J; Jörres A; Lage C; Schaub TP; Passlick-Deetjen J; Breborowicz A; Grzegorzewska A; Ksiazek A; Liberek T; Lichodziejewska-Niemierko M; Majdan M; Rutkowski B; Stompór T; Sulowicz W
Nephrol Dial Transplant; 2004 Apr; 19(4):917-24. PubMed ID: 15031350
[TBL] [Abstract][Full Text] [Related]
43. TGF-β1-VEGF-A pathway induces neoangiogenesis with peritoneal fibrosis in patients undergoing peritoneal dialysis.
Kariya T; Nishimura H; Mizuno M; Suzuki Y; Matsukawa Y; Sakata F; Maruyama S; Takei Y; Ito Y
Am J Physiol Renal Physiol; 2018 Feb; 314(2):F167-F180. PubMed ID: 28978530
[TBL] [Abstract][Full Text] [Related]
44. Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
Nishina M; Endoh M; Suzuki D; Tanabe R; Endoh H; Hirahara I; Sakai H
Clin Exp Nephrol; 2004 Dec; 8(4):339-43. PubMed ID: 15619033
[TBL] [Abstract][Full Text] [Related]
45. [Salvia Miltiorrhiza injection relieves peritoneal dialysis solution-induced injuries of peritoneal structure and function in rats].
Zhang D; Shu J; Wang Y
Zhong Xi Yi Jie He Xue Bao; 2008 May; 6(5):517-23. PubMed ID: 18471419
[TBL] [Abstract][Full Text] [Related]
46. A commercially available PD fluid with high pH and low GDP induces different morphological changes of rat peritoneum in intermittent PD.
Jonasson P; Braide M
Adv Perit Dial; 1998; 14():48-53. PubMed ID: 10649690
[TBL] [Abstract][Full Text] [Related]
47. Acute effects of peritoneal dialysis solutions in the mesenteric microcirculation.
Frajewicki V; Brod V; Kushnir D; Kohan R; Bitterman H
Transl Res; 2009 May; 153(5):249-56. PubMed ID: 19375686
[TBL] [Abstract][Full Text] [Related]
48. Tranexamic acid: a "diuretic" for the peritoneal membrane?
Suzuki K; Karino T; Namoto S; Wada M; Wakamiya Y; Yamamoto T
Adv Perit Dial; 2000; 16():42-5. PubMed ID: 11045259
[TBL] [Abstract][Full Text] [Related]
49. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
[TBL] [Abstract][Full Text] [Related]
50. The association between the vascular endothelial growth factor-to-cancer antigen 125 ratio in peritoneal dialysis effluent and the epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis.
Do JY; Kim YL; Park JW; Chang KA; Lee SH; Ryu DH; Kim CD; Park SH; Yoon KW
Perit Dial Int; 2008 Jun; 28 Suppl 3():S101-6. PubMed ID: 18552237
[TBL] [Abstract][Full Text] [Related]
51. Time to reconsider saline as the ideal rinsing solution during abdominal surgery.
Połubinska A; Winckiewicz M; Staniszewski R; Breborowicz A; Oreopoulos DG
Am J Surg; 2006 Sep; 192(3):281-5. PubMed ID: 16920418
[TBL] [Abstract][Full Text] [Related]
52. Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum.
Duman S; Wieczorowska-Tobis K; Styszynski A; Kwiatkowska B; Breborowicz A; Oreopoulos DG
Adv Perit Dial; 2004; 20():31-6. PubMed ID: 15384791
[TBL] [Abstract][Full Text] [Related]
53. Effects of glucose and plasminogen activator inhibitor-1 on collagen metabolism in the peritoneum.
Higuchi C; Tanihata Y; Nishimura H; Naito T; Sanaka T
Ther Apher Dial; 2005 Apr; 9(2):173-81. PubMed ID: 15828931
[TBL] [Abstract][Full Text] [Related]
54. What does the dialysate level of matrix metalloproteinase 2 tell us?
Ertilav M; Timur O; Hür E; Bozkurt D; Nar H; Kologlu T; Sen S; Duman S
Adv Perit Dial; 2011; 27():6-10. PubMed ID: 22073820
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of peritoneal transport and membrane status in peritoneal dialysis: focus on incident fast transporters.
Rodrigues AS; Martins M; Korevaar JC; Silva S; Oliveira JC; Cabrita A; Castro e Melo J; Krediet RT
Am J Nephrol; 2007; 27(1):84-91. PubMed ID: 17284895
[TBL] [Abstract][Full Text] [Related]
56. Pyridoxal phosphate and hepatocyte growth factor prevent dialysate-induced peritoneal damage.
Nakamura S; Niwa T
J Am Soc Nephrol; 2005 Jan; 16(1):144-50. PubMed ID: 15563557
[TBL] [Abstract][Full Text] [Related]
57. Biocompatibility of peritoneal dialysis fluid and influence of compositions on peritoneal fibrosis.
Higuchi C; Nishimura H; Sanaka T
Ther Apher Dial; 2006 Aug; 10(4):372-9. PubMed ID: 16911191
[TBL] [Abstract][Full Text] [Related]
58. [Effects of high glucose on the cell proliferation, damage and cytokine in human peritoneal mesothelial cells].
Liu YH; Liu FY; Zhang H; Peng YM; Yuan F; Liu H; Chen MC; Zhuo L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Aug; 31(4):575-9. PubMed ID: 16951522
[TBL] [Abstract][Full Text] [Related]
59. Rosiglitazone, a peroxisome proliferator-activated receptor agonist, improves peritoneal alterations resulting from an encapsulated peritoneal sclerosis model.
Bozkurt D; Taskin H; Sezak M; Biçak S; Sen S; Ok E; Duman S
Adv Perit Dial; 2008; 24():32-8. PubMed ID: 18985998
[TBL] [Abstract][Full Text] [Related]
60. The role of the TGF/Smad signaling pathway in peritoneal fibrosis induced by peritoneal dialysis solutions.
Yao Q; Pawlaczyk K; Ayala ER; Styszynski A; Breborowicz A; Heimburger O; Qian JQ; Stenvinkel P; Lindholm B; Axelsson J
Nephron Exp Nephrol; 2008; 109(2):e71-8. PubMed ID: 18600031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
